1az2: Difference between revisions
No edit summary |
No edit summary |
||
| Line 26: | Line 26: | ||
[[Category: oxidoreductase]] | [[Category: oxidoreductase]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Oct 30 14: | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Tue Oct 30 14:53:04 2007'' | ||
Revision as of 15:48, 30 October 2007
|
CITRATE BOUND, C298A/W219Y MUTANT HUMAN ALDOSE REDUCTASE
OverviewOverview
It is generally expected that only one inhibitor molecule will bind to an, enzyme active site. In fact, specific drug design theories depend upon, this assumption. Here, we report the binding of two molecules of an, inhibitor to the same active site which we observed in the 1.8 A, resolution structure of the drug Alrestatin bound to a mutant of human, aldose reductase. The two molecules of Alrestatin bind to the active site, in a stacked arrangement (a double-decker). This stack positions the, carboxylic acid of one drug molecule near the NADP+ cofactor at a, previously determined anion binding site and the carboxylic acid of the, second drug molecule near the carboxy-terminal tail of the enzyme. We, propose that interactions of inhibitors with the carboxy-terminal loop of, aldose ... [(full description)]
About this StructureAbout this Structure
1AZ2 is a [Single protein] structure of sequence from [Homo sapiens] with NAP and CIT as [ligands]. Active as [Aldehyde reductase], with EC number [1.1.1.21]. Structure known Active Site: ACT. Full crystallographic information is available from [OCA].
ReferenceReference
The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant., Harrison DH, Bohren KM, Petsko GA, Ringe D, Gabbay KH, Biochemistry. 1997 Dec 23;36(51):16134-40. PMID:9405046
Page seeded by OCA on Tue Oct 30 14:53:04 2007